Index Entries

Allan S. Cunningham
March 16, 2021
BMJ (British Medical Journal)

Cunningham is a retired pediatrician. 

Rapid response to:

Covid-19: WHO says rollout of AstraZeneca vaccine should continue, as Europe divides over safety
https://www.bmj.com/content/372/bmj.n728 

“Recently a pediatric colleague sent me this preprint link to a Danish cohort study of the Pfizer Covid-19 vaccine in long-term care facility residents and healthcare workers. (https://www.medrxiv.org/content/10.1101/2021.03.08.21252200v1) It showed real-world effectiveness of two doses of the mRNA vaccine: 64% and 90% VE in the two groups respectively beyond seven days after the second dose.

However, from 0 to 14 days after the first dose the risk of Covid-19 infection was actually increased in vaccine recipients: in the LTCF residents VE was -40%, CI -62% to -2%; among healthcare workers VE was -104%, CI -118% to -91%.(Table 2)….By contrast, statistics for the 0 to 14 days after the first dose were not reported in the randomized trials of the Pfizer, Moderna, or AstraZeneca vaccines. (Polack et al, NEJM 2020;383:2603. Baden et al, NEJM 2021;384:403. Voysel et al, Lancet 2021;397:92) Why not? Are the manufacturers hiding negative data?”

document
clinical cases,clinical trials,COVID-19,manufacturers,vaccines